DRREDDY.NSライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (8 5月 2024 @ 15:10):

Stats
本日の出来高	674 338
平均出来高	362 574
時価総額	1 004.08B
EPS	INR0 ( 2024-05-06 )
次の収益日	( INR0 ) 2024-07-26
Last Dividend	INR40.00 ( 2023-07-11 )
Next Dividend	INR0 ( N/A )
P/E	19.24
ATR14	INR5.78 (0.10%)

ボリューム相関

長: 0.17 (neutral)

短: -0.63 (weak negative)

Signal:(53.927) Neutral

Dr. Reddy's Laboratories 相関

10 最も正の相関
SETF10GILT.NS	0.933
ASHIANA.NS	0.919
MOGSEC.NS	0.915
ADORWELD.NS	0.905
BHARATWIRE.NS	0.903
IZMO.NS	0.898
BAJAJ-AUTO.NS	0.893
GTNTEX.NS	0.884
CYIENT.NS	0.883
MASPTOP50.NS	0.882

10 最も負の相関
STARTECK.NS	-0.898
SUNCLAYLTD.NS	-0.875
SCI.NS	-0.87
TEAMLEASE.NS	-0.856
ORTINLAB.NS	-0.853
MOHOTAIND.NS	-0.851
EASTSILK.NS	-0.851
ROLTA.NS	-0.844
CLNINDIA.NS	-0.844
GENESYS.NS	-0.839

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Dr. Reddy's Laboratories 相関 - 通貨/商品

0.84
( strong )

0.77
( moderate )

0.14
( neutral )

0.86
( strong )

-0.01
( neutral )

0.00
( neutral )

Dr. Reddy's Laboratories 財務諸表

Annual	2022
収益:	INR245.88B
総利益:	INR169.30B (68.86 %)
EPS:	INR271.43

FY	2022
収益:	INR245.88B
総利益:	INR169.30B (68.86 %)
EPS:	INR271.43

FY	2022
収益:	INR214.39B
総利益:	INR113.84B (53.10 %)
EPS:	INR142.08

FY	2021
収益:	INR189.72B
総利益:	INR103.08B (54.33 %)
EPS:	INR103.94

Financial Reports:

No articles found.

Dr. Reddy's Laboratories Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
INR60.00 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR40.00 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)

Dr. Reddy's Laboratories Dividend Information - Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 6.28 - Stable (25.68%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	INR2.50	2003-08-08
Last Dividend	INR40.00	2023-07-11
Next Dividend	INR0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	23	--
Total Paid Out	INR363.00	--
Avg. Dividend % Per Year	0.62%	--
Score	3.63	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	6.28
Div. Directional Score	8.85	--

Next Divdend (Est)
(2024-07-01)

INR42.96 Estimate 3.12 %

Dividend Stability

0.25 Very Poor

Dividend Score

3.63

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield
2003	INR0	0.00%
2004	INR0	0.00%
2005	INR0	0.00%
2006	INR0	0.00%
2007	INR0	0.00%
2008	INR0	0.00%
2009	INR0	0.00%
2010	INR0	0.00%
2011	INR0	0.00%
2012	INR0	0.00%
2013	INR0	0.00%
2014	INR0	0.00%
2015	INR0	0.00%
2016	INR0	0.00%
2017	INR0	0.00%
2018	INR40.00	1.93%
2019	INR20.00	0.77%
2020	INR25.00	0.87%
2021	INR25.00	0.48%
2022	INR60.00	1.24%
2023	INR40.00	0.94%
2024	INR0	0.00%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for NSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
TFCILTD.NS	Dividend Junior	2023-08-11	Annually	23	1.38%
ORIENTBELL.NS	Dividend Junior	2023-07-18	Annually	18	0.14%
IRCON.NS	Dividend Knight	2023-09-05	Semi-Annually	6	3.39%
CROMPTON.NS	Dividend Junior	2023-07-06	Annually	8	0.52%
SHIVALIK.NS	Dividend Junior	2023-09-22	Annually	3	0.03%
MANORAMA.NS	Dividend Junior	2023-09-11	Insufficient data to determine frequency	2	0.07%
GRAVITA.NS	Dividend Junior	2023-09-04	Annually	14	0.72%
BAJAJHLDNG.NS	Dividend Knight	2023-09-29	Annually	22	1.20%
UBL.NS	Dividend Junior	2023-08-03	Annually	17	0.27%
POLYCAB.NS	Dividend Knight	2023-06-21	Annually	6	0.50%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.192	1.500	6.15	9.23	[0 - 0.5]
returnOnAssetsTTM	0.140	1.200	5.33	6.40	[0 - 0.3]
returnOnEquityTTM	0.209	1.500	8.79	10.00	[0.1 - 1]
payoutRatioTTM	0.127	-1.000	8.73	-8.73	[0 - 1]
currentRatioTTM	2.55	0.800	2.26	1.809	[1 - 3]
quickRatioTTM	1.800	0.800	4.12	3.30	[0.8 - 2.5]
cashRatioTTM	0.0784	1.500	-0.675	-1.013	[0.2 - 2]
debtRatioTTM	0.0532	-1.500	9.11	-10.00	[0 - 0.6]
interestCoverageTTM	44.26	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	321.84	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	172.31	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0.0741	-1.500	9.70	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.641	1.000	2.66	2.66	[0.2 - 0.8]
operatingProfitMarginTTM	0.240	1.000	7.20	7.20	[0.1 - 0.6]
cashFlowToDebtRatioTTM	2.70	1.000	10.00	10.00	[0.2 - 2]
assetTurnoverTTM	0.728	0.800	8.48	6.79	[0.5 - 2]
Total Score				11.41

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	20.07	1.000	8.07	0	[1 - 100]
returnOnEquityTTM	0.209	2.50	9.22	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	172.31	2.00	10.00	10.00	[0 - 30]
dividendYielPercentageTTM	0.636	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	321.84	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	0.127	1.500	8.73	-8.73	[0 - 1]
pegRatioTTM	0.220	1.500	-1.863	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.198	1.000	7.56	0	[0.1 - 0.5]
Total Score				6.28

Dr. Reddy's Laboratories

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. Its Proprietary Products segment focuses on the research and development of differentiated formulations. The Others segment engages in developing therapies in the fields of oncology and inflammation. The therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. The company has a collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology targets. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.